These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 36737752)
1. Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. Nuzzo PV; Pederzoli F; Saieva C; Zanardi E; Fotia G; Malgeri A; Rossetti S; Valenca Bueno L; Andrade LMQS; Patrikidou A; Mestre RP; Modesti M; Pignata S; Procopio G; Fornarini G; De Giorgi U; Russo A; Francini E; J Transl Med; 2023 Feb; 21(1):75. PubMed ID: 36737752 [TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of volume of disease on patients receiving enzalutamide Nuzzo PV; Ravera F; Saieva C; Zanardi E; Fotia G; Malgeri A; Rossetti S; Valença LB; Oliveira TM; Vauchier C; Pereira Mestre R; Modesti M; Patrikidou A; Pignata S; Procopio G; Fornarini G; De Giorgi U; Russo A; Francini E Ther Adv Med Oncol; 2023; 15():17588359231156147. PubMed ID: 36895852 [TBL] [Abstract][Full Text] [Related]
3. Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study. Fotia G; Saieva C; Lee-Ying R; Patrikidou A; Nuzzo PV; Zanardi E; Rossetti S; Davidsohn M; Eid M; El Zarif T; McClure H; Spinelli GP; Damassi A; Murianni V; Vauchier C; Oliveira TM; Malgeri A; Modesti M; Mestre RP; Valenca L; Ravi P; Santini D; Pignata S; De Giorgi U; Sweeney C; Heng D; Procopio G; Russo A; Francini E; Clin Genitourin Cancer; 2024 Oct; 22(5):102185. PubMed ID: 39217072 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer. Emamekhoo H; Barata PC; Edwin NC; Woo KM; Grivas P; Garcia JA Clin Genitourin Cancer; 2018 Dec; 16(6):429-436. PubMed ID: 30236961 [TBL] [Abstract][Full Text] [Related]
5. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. Francini E; Montagnani F; Nuzzo PV; Gonzalez-Velez M; Alimohamed NS; Rosellini P; Moreno-Candilejo I; Cigliola A; Rubio-Perez J; Crivelli F; Shaw GK; Zhang L; Petrioli R; Bengala C; Francini G; Garcia-Foncillas J; Sweeney CJ; Higano CS; Bryce AH; Harshman LC; Lee-Ying R; Heng DYC JAMA Netw Open; 2021 Jul; 4(7):e2116536. PubMed ID: 34292336 [TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611 [TBL] [Abstract][Full Text] [Related]
7. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. Massoudi M; Balk M; Yang H; Bui CN; Pandya BJ; Guo J; Song Y; Wu EQ; Brown B; Barlev A; Flanders S J Med Econ; 2017 Feb; 20(2):121-128. PubMed ID: 27570999 [TBL] [Abstract][Full Text] [Related]
8. [Early- vs. late-onset treatment using abiraterone acetate plus prednisone in chemo-naïve, asymptomatic or mildly symptomatic patients with metastatic CRPC after androgen deprivation therapy]. Merseburger AS; Rüssel C; Belz H; Spiegelhalder P; Feyerabend S; Tran N; Kruetzfeldt K; Baurecht W; Bögemann M Aktuelle Urol; 2020 Dec; 51(6):562-571. PubMed ID: 32268436 [TBL] [Abstract][Full Text] [Related]
9. Enzalutamide versus abiraterone acetate in the development of new-onset or worsening type 2 diabetes mellitus in patients with metastatic castration-resistant prostate cancer: EVADE study. Bahl A; Sodatonou H; Snjider R; Chilelli A; Pranzo A; Martins K; Merseburger A; Rozario N; Crawley D World J Urol; 2024 Oct; 42(1):584. PubMed ID: 39422767 [TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030 [TBL] [Abstract][Full Text] [Related]
11. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide. Petrylak DP; Vaishampayan UN; Patel KR; Higano CS; Albany C; Dawson NA; Mehlhaff BA; Quinn DI; Nordquist LT; Wagner VJ; Siegel J; Trandafir L; Sartor O ESMO Open; 2021 Apr; 6(2):100082. PubMed ID: 33744812 [TBL] [Abstract][Full Text] [Related]
12. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Saad F; Efstathiou E; Attard G; Flaig TW; Franke F; Goodman OB; Oudard S; Steuber T; Suzuki H; Wu D; Yeruva K; De Porre P; Brookman-May S; Li S; Li J; Thomas S; Bevans KB; Mundle SD; McCarthy SA; Rathkopf DE; Lancet Oncol; 2021 Nov; 22(11):1541-1559. PubMed ID: 34600602 [TBL] [Abstract][Full Text] [Related]
13. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone. Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280 [TBL] [Abstract][Full Text] [Related]
14. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882 [TBL] [Abstract][Full Text] [Related]
15. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231 [TBL] [Abstract][Full Text] [Related]
16. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe. de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372 [TBL] [Abstract][Full Text] [Related]
17. Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study. Thiery-Vuillemin A; Poulsen MH; Lagneau E; Ploussard G; Birtle A; Dourthe LM; Beal-Ardisson D; Pintus E; Trepiakas R; Lefresne F; Lukac M; Van Sanden S; Pissart G; Reid A; Eur Urol; 2020 Mar; 77(3):380-387. PubMed ID: 31594705 [TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer. Francini E; Yip S; Ahmed S; Li H; Ardolino L; Evan CP; Kaymakcalan M; Shaw GK; Kantoff PW; Taplin ME; Alimohamed NS; Joshua AM; Heng DYC; Sweeney CJ Clin Genitourin Cancer; 2018 Apr; 16(2):130-134. PubMed ID: 29331381 [TBL] [Abstract][Full Text] [Related]
19. Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT). Shore ND; Saltzstein D; Sieber P; Mehlhaff B; Gervasi L; Phillips J; Wong YN; Pei H; McGowan T Clin Genitourin Cancer; 2019 Dec; 17(6):457-463.e6. PubMed ID: 31473120 [TBL] [Abstract][Full Text] [Related]
20. Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer. Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S Clin Genitourin Cancer; 2018 Apr; 16(2):142-148. PubMed ID: 29042308 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]